Now, the growing buzz around the use of GLP-1 medications like Ozempic to treat alcohol use disorder finally has new clinical ...

As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

They also discovered that cigarette use declined among a subgroup of smokers in the study, lending weight to the hypothesis ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...

GLP1RA mimic the GLP-1 hormone in the body that helps control insulin and blood glucose levels and promotes feelings of satiety. GLP-1 binds to GLP1R on cells in the brain and pancreas.

The case for GLP-1 drugs like Ozempic possibly causing blindness is building. A new paper out this week describes several people who developed eye conditions soon after they began taking semaglutide ...

Scientists remain puzzled as to why some individuals taking popular weight loss and diabetes medications such as Ozempic and ...

Citi analyst David Lebowitz initiated coverage of Viking Therapeutics (VKTX) with a Neutral rating and $38 price target Viking’s VK2735 is an ...

NLY01, a long-acting GLP-1 agonist, recently completed a 36-week ... incretin-based peptide drugs for obesity. Offering a new mechanism for treating fibrotic disease, TLY012 directly targets ...